219 related articles for article (PubMed ID: 17018774)
21. Microtubules and resistance to tubulin-binding agents.
Kavallaris M
Nat Rev Cancer; 2010 Mar; 10(3):194-204. PubMed ID: 20147901
[TBL] [Abstract][Full Text] [Related]
22. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.
Gan PP; McCarroll JA; Po'uha ST; Kamath K; Jordan MA; Kavallaris M
Mol Cancer Ther; 2010 May; 9(5):1339-48. PubMed ID: 20442307
[TBL] [Abstract][Full Text] [Related]
23. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?
English DP; Roque DM; Santin AD
Expert Rev Anticancer Ther; 2013 Jan; 13(1):63-74. PubMed ID: 23259428
[TBL] [Abstract][Full Text] [Related]
24. Interaction of epothilone B (patupilone) with microtubules as detected by two-dimensional solid-state NMR spectroscopy.
Kumar A; Heise H; Blommers MJ; Krastel P; Schmitt E; Petersen F; Jeganathan S; Mandelkow EM; Carlomagno T; Griesinger C; Baldus M
Angew Chem Int Ed Engl; 2010 Oct; 49(41):7504-7. PubMed ID: 20809556
[No Abstract] [Full Text] [Related]
25. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
[TBL] [Abstract][Full Text] [Related]
26. Microtubule-stabilizing activity of zampanolide, a potent macrolide isolated from the Tongan marine sponge Cacospongia mycofijiensis.
Field JJ; Singh AJ; Kanakkanthara A; Halafihi T; Northcote PT; Miller JH
J Med Chem; 2009 Nov; 52(22):7328-32. PubMed ID: 19877653
[TBL] [Abstract][Full Text] [Related]
27. Microtubule-associated proteins as targets in cancer chemotherapy.
Bhat KM; Setaluri V
Clin Cancer Res; 2007 May; 13(10):2849-54. PubMed ID: 17504982
[TBL] [Abstract][Full Text] [Related]
28. Tubulin/microtubules: still a promising target for new chemotherapeutic agents.
Giannakakou P; Sackett D; Fojo T
J Natl Cancer Inst; 2000 Feb; 92(3):182-3. PubMed ID: 10655426
[No Abstract] [Full Text] [Related]
29. 7-Diethylamino-3(2'-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells.
Kim SN; Kim NH; Park YS; Kim H; Lee S; Wang Q; Kim YK
Biochem Pharmacol; 2009 Jun; 77(12):1773-9. PubMed ID: 19428332
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth.
Prudent R; Vassal-Stermann E; Nguyen CH; Pillet C; Martinez A; Prunier C; Barette C; Soleilhac E; Filhol O; Beghin A; Valdameri G; Honoré S; Aci-Sèche S; Grierson D; Antonipillai J; Li R; Di Pietro A; Dumontet C; Braguer D; Florent JC; Knapp S; Bernard O; Lafanechère L
Cancer Res; 2012 Sep; 72(17):4429-39. PubMed ID: 22761334
[TBL] [Abstract][Full Text] [Related]
31. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
32. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
Chu SW; Badar S; Morris DL; Pourgholami MH
Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910
[TBL] [Abstract][Full Text] [Related]
33. Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc.
Mackenzie GG; Keen CL; Oteiza PI
J Neurochem; 2006 Oct; 99(2):402-15. PubMed ID: 17029595
[TBL] [Abstract][Full Text] [Related]
34. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
35. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
36. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding.
Gupta KK; Bharne SS; Rathinasamy K; Naik NR; Panda D
FEBS J; 2006 Dec; 273(23):5320-32. PubMed ID: 17069615
[TBL] [Abstract][Full Text] [Related]
37. [Antimicrotubule agents can activate different apoptotic pathways].
Kisurina-Evgen'eva OP; Briantseva SA; Stil' AA; Onishchenko GE
Biofizika; 2006; 51(5):875-9. PubMed ID: 17131827
[TBL] [Abstract][Full Text] [Related]
38. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
39. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
Fürst R; Vollmar AM
Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
[TBL] [Abstract][Full Text] [Related]
40. CENP-E checks in microtubule-drug resistance.
Chanel-Vos C; Giannakakou P
Cell Cycle; 2010 Apr; 9(8):1456. PubMed ID: 20421712
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
